Ninlaro (Ixazomib): First Oral Proteasome Inhibitor Approved for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma.
作者信息
Raedler Lisa A
出版信息
Am Health Drug Benefits. 2016 Mar;9(Spec Feature):102-5.
Abstract
摘要
相似文献
1
Ninlaro (Ixazomib): First Oral Proteasome Inhibitor Approved for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma.
Am Health Drug Benefits. 2016 Mar;9(Spec Feature):102-5.
2
[Pharmacological characteristics and clinical study results of the oral proteasome inhibitor ixazomib (NINLARO capsules; 2.3 mg, 3 mg, and 4 mg)].
Nihon Yakurigaku Zasshi. 2018;151(4):166-178. doi: 10.1254/fpj.151.166.
3
Ixazomib: A Review in Relapsed and/or Refractory Multiple Myeloma.
Target Oncol. 2017 Aug;12(4):535-542. doi: 10.1007/s11523-017-0504-7.
4
Ixazomib: First Global Approval.
Drugs. 2016 Mar;76(3):405-11. doi: 10.1007/s40265-016-0548-5.
5
Exposure-safety-efficacy analysis of single-agent ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma: dose selection for a phase 3 maintenance study.
Invest New Drugs. 2016 Jun;34(3):338-46. doi: 10.1007/s10637-016-0346-7. Epub 2016 Apr 2.
6
Ixazomib for the treatment of multiple myeloma.
Expert Opin Investig Drugs. 2015;24(9):1287-98. doi: 10.1517/13543784.2015.1065250. Epub 2015 Jul 3.
7
The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma.
Future Oncol. 2015;11(8):1153-68. doi: 10.2217/fon.15.9.
8
Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses.
Target Oncol. 2017 Oct;12(5):643-654. doi: 10.1007/s11523-017-0524-3.
9
Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone . placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1.
Haematologica. 2017 Oct;102(10):1767-1775. doi: 10.3324/haematol.2017.170118. Epub 2017 Jul 27.
10
Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study.
Ann Hematol. 2020 Jun;99(6):1273-1281. doi: 10.1007/s00277-020-03985-9. Epub 2020 Mar 20.
引用本文的文献
1
Prognostic Value of PSMB5 and Correlations with LC3II and Reactive Oxygen Species Levels in the Bone Marrow Mononuclear Cells of Bortezomib-Resistant Multiple Myeloma Patients.
Curr Issues Mol Biol. 2025 Jan 6;47(1):32. doi: 10.3390/cimb47010032.
2
Recent advances in targeted drug delivery systems for multiple myeloma.
J Control Release. 2024 Dec;376:215-230. doi: 10.1016/j.jconrel.2024.10.003. Epub 2024 Oct 12.
3
The SAR analysis of dietary polyphenols and their antagonistic effects on bortezomib at physiological concentrations.
Front Pharmacol. 2024 Jul 25;15:1403424. doi: 10.3389/fphar.2024.1403424. eCollection 2024.
4
Risk of atrial fibrillation in patients with multiple myeloma: what is known and directions for future study.
Egypt Heart J. 2024 Feb 1;76(1):14. doi: 10.1186/s43044-023-00434-6.
5
Covalent-reversible peptide-based protease inhibitors. Design, synthesis, and clinical success stories.
Amino Acids. 2023 Dec;55(12):1775-1800. doi: 10.1007/s00726-023-03286-1. Epub 2023 Jun 17.
6
Identification of as a genetic modifier of fragile X-associated tremor/ataxia syndrome.
Proc Natl Acad Sci U S A. 2022 May 31;119(22):e2118124119. doi: 10.1073/pnas.2118124119. Epub 2022 May 26.
7
Approaches and Challenges in the Management of Multiple Myeloma in the Very Old: Future Treatment Prospects.
Front Med (Lausanne). 2021 Feb 25;8:612696. doi: 10.3389/fmed.2021.612696. eCollection 2021.
8
Belantamab Mafodotin to Treat Multiple Myeloma: A Comprehensive Review of Disease, Drug Efficacy and Side Effects.
Curr Oncol. 2021 Jan 21;28(1):640-660. doi: 10.3390/curroncol28010063.
9
A High-Content Screening Assay for the Discovery of Novel Proteasome Inhibitors from Formosan Soft Corals.
Mar Drugs. 2018 Oct 21;16(10):395. doi: 10.3390/md16100395.
10
Sub-picomolar Inhibition of HIV-1 Protease with a Boronic Acid.
J Am Chem Soc. 2018 Oct 31;140(43):14015-14018. doi: 10.1021/jacs.8b07366. Epub 2018 Oct 22.
本文引用的文献
1
Multiple myeloma and physical activity: a scoping review.
BMJ Open. 2015 Nov 27;5(11):e009576. doi: 10.1136/bmjopen-2015-009576.
2
Multiple myeloma: the bone marrow microenvironment and its relation to treatment.
Br J Biomed Sci. 2013;70(3):110-20. doi: 10.1080/09674845.2013.11669945.
3
New strategies in the treatment of multiple myeloma.
Clin Cancer Res. 2013 Jul 1;19(13):3337-44. doi: 10.1158/1078-0432.CCR-12-1881. Epub 2013 Mar 20.
4
The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenance treatment.
Oncologist. 2013;18(1):27-36. doi: 10.1634/theoncologist.2011-0380. Epub 2013 Jan 8.
5
Health care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: findings using real-world claims data.
Oncologist. 2013;18(1):37-45. doi: 10.1634/theoncologist.2012-0113. Epub 2013 Jan 8.
6
Improved survival in multiple myeloma and the impact of novel therapies.
Blood. 2008 Mar 1;111(5):2516-20. doi: 10.1182/blood-2007-10-116129. Epub 2007 Nov 1.
Zotero 插件